Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 3Breast 3Sarcoma 2Gynecologic 2Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Stomach Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × pamiparib × Gastrointestinal × Clear all
NCT03150810 2024-12-20

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

BeiGene

Phase 1 Completed
139 enrolled 36 charts
BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03427814 2024-10-26

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

BeiGene

Phase 2 Completed
136 enrolled 16 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡